Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Parvovirus particles as platforms for protein presentation

K Miyamura1, S Kajigaya, M Momoeda

  • 1Hematology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892.

Proceedings of the National Academy of Sciences of the United States of America
|August 30, 1994
PubMed
Summary

Researchers engineered parvovirus B19 empty capsids to display hen egg white lysozyme (HEL). This demonstrates the potential for incorporating foreign proteins into B19 capsids for applications in medicine and gene therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship of Lesion Location to Postoperative Steroid Use in Eosinophilic Chronic Rhinosinusitis.

The Laryngoscope·2023
Same author

Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BM.

Leukemia·2017
Same author

Increase of bone marrow macrophages and CD8<sup>+</sup> T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantation.

Bone marrow transplantation·2017
Same author

Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes.

Leukemia·2017
Same author

Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Bone marrow transplantation·2017
Same author

Autoimmune-like hepatitis after allogeneic hematopoietic stem cell transplantation: humoral hepatic GvHD.

Bone marrow transplantation·2016

Area of Science:

  • Virology
  • Biotechnology
  • Immunology

Background:

  • Human pathogenic parvovirus B19 (B19) empty capsids can be produced using a baculovirus system.
  • B19 capsids consist of major capsid protein (VP2) and minor capsid protein (VP1).
  • VP1 contains a unique N-terminal region, with a portion exposed on the capsid surface, and is not essential for capsid assembly.

Purpose of the Study:

  • To investigate the feasibility of incorporating heterologous proteins into B19 empty capsids.
  • To evaluate the surface display and functionality of an incorporated foreign protein.
  • To explore potential applications of engineered B19 capsids in vaccine development, cell targeting, and gene therapy.

Main Methods:

  • Construction of recombinant baculoviruses encoding B19 VP2 fused with hen egg white lysozyme (HEL) in place of the VP1 unique region.

Related Experiment Videos

  • Expression of recombinant capsids in insect cells via cotransfection with VP2 baculovirus.
  • Purification of capsids using density sedimentation.
  • Characterization of HEL incorporation and surface display using immunoprecipitation, ELISA, and immune electron microscopy.
  • Assessment of enzymatic activity and immunogenicity in rabbits.

    • Main Results:

    • Recombinant B19 capsids successfully incorporated hen egg white lysozyme (HEL).
    • External presentation of HEL on the capsid surface was confirmed by multiple immunological assays.
    • The engineered capsids exhibited enzymatic activity and elicited an antibody response against HEL in rabbits.
    • These findings validate the strategy of displaying functional heterologous proteins on the B19 capsid surface.

    Conclusions:

    • Parvovirus B19 empty capsids can be engineered to display functional heterologous proteins, such as hen egg white lysozyme (HEL).
    • The successful surface display and immunogenicity of HEL demonstrate the potential of this platform for developing novel vaccines.
    • Engineered B19 capsids offer promising avenues for targeted drug delivery and gene therapy applications.